DOI: 10.1111/tog.

12180 2015;17:99–104
The Obstetrician & Gynaecologist
Review
http://onlinetog.org

Diagnosis, pathophysiology and management of

premenstrual syndrome
a, b c d
Sally Walsh MBCHB, * Elgerta Ismaili MBBS, Bushra Naheed MBBS DGO, Shaugn O’Brien DSc MD FRCOG
a
FY2, University Hospital North Staffordshire, City General Hospital, Stoke-on-Trent ST4 6QG, UK
b
SHO, Royal London Hospital, Whitechapel Road, London E1 1BB, UK
c
PhD student (clinical science), Institute for Science and Technology in Medicine, Keele University, Stoke-on-Trent ST4 7QB, UK
d
Professor of Obstetrics and Gynaecology, Keele University School of Medicine, Clinical Director Obstetrics and Gynaecology and Consultant
Obstetrician and Gynaecologist University Hospital North Staffordshire NHS Trust, City General Hospital, Newcastle Road, Stoke-on-Trent ST4
6QG, UK
*Correspondence: Sally Walsh. Email: sally.walsh@uhns.nhs.uk

Accepted on 28 January 2015

Key content  How to treat PMS, including the different treatment options
 An overview of current information available on premenstrual available and discussion about side effects and benefits.
syndrome (PMS), which is in accordance with the new RCOG
Ethical issues
Green-top Guideline. 
 Definition of PMS and explanation about the different types of
Discussion about the long-term risks of GnRH analogue use, and
the impact of long-term estrogen deficiency following a
premenstrual disorders.
 How to accurately diagnose PMS.
bilateral salpingoophorectomy.
 Misdiagnosed PMS in patients with underlying psychiatric and
 Discussion about various treatment options available in
medical conditions.
accordance with the current literature.
Keywords: epidemiology / gynaecology / HRT regimens /
Learning objectives

menopause / pathology / psychiatry
Develop an understanding of the pathophysiology behind PMS.
 How to diagnose PMS accurately and understand the different
classifications of PMS.

Please cite this paper as: Walsh S, Ismaili E, Naheed B, O’Brien S. Diagnosis, pathophysiology and management of premenstrual syndrome. The Obstetrician &
Gynaecologist 2015;17:99–104.

Introduction and variant. In all PMD, symptoms should cause impairment

Premenstrual syndrome (PMS) is defined as a condition with
emotional, physical and behavioural symptoms that increase
in severity during the luteal phase of the menstrual cycle, and
resolve by the end of menstruation. By definition, there must
be a symptom-free interval after menstruation and
before ovulation.1,2
Symptoms are usually up to 14 days before the start of
menses, causing impairment of life, with anger and irritability
being the most severe and longer lasting symptoms.3,4
Studies have shown that 3–8% of menstruating women are
affected by PMS, and that 15–20% of women meet the
criteria for subclinical PMS.5
Classification
The International Society for Premenstrual Disorders
(ISPMD) defined precise criteria for diagnosing
premenstrual disorders (PMD), and divided PMS into core
of daily activities at work, social activities and
interpersonal relationships.
Core (or typical) PMD is associated with spontaneous
ovulatory menstrual cycles and may be subdivided into
predominantly physical symptoms, predominantly
psychological or mixed.1,6,7
Women whose symptoms are predominantly psychological
or mixed may also fulfil the criteria for premenstrual
dysphoric disorder.
Variants of PMD encompass more complex features,
divided into the four following categories: premenstrual
exacerbation of an underlying condition; PMS in the absence
of menstruation; progestogen-induced PMS; and PMS with
anovulatory ovarian activity.6,7
For an accurate diagnosis of PMS, symptoms must
occur regularly in ovulating women during the luteal
phase of the cycle, with resolution by the end of
menstruation (Box 1).6

ª 2015 Royal College of Obstetricians and Gynaecologists 99

 An overview of the current management of PMS
Box 1. Criteria for diagnosing core premenstrual disorder6
 It is precipitated by ovulation
 Symptoms are not defined, although typical symptoms exist
 Any number of symptoms can be present
 Physical and psychological symptoms are important
 Symptoms recur in the luteal phase
 Symptoms disappear by the end of menstruation
 A symptom-free week occurs between menstruation and ovulation
 Symptoms must be prospectively rated
 Symptoms are not an exacerbation of an underlying psychological
or physical disorder
 Symptoms cause significant distress and impairment of daily
activities, such as work commitments, social interactions and
family activities.
Pathology
Research is yet to find a conclusive pathophysiological
explanation for PMS. Early theories thought there were
abnormalities in ovarian sex steroid levels, however this has
been disproved, as no differences have been demonstrated
between symptomatic and asymptomatic women, and no
study has demonstrated differences in progesterone levels.5,9
It is recognised that aetiology is centred around the ovarian
cycle, and this theory is supported by the lack of symptoms
before puberty, during pregnancy, after menopause, and
during treatment with gonanotrophin-releasing hormone
(GnRH) analogues.
Sex steroids easily pass the blood–brain barrier, and their
receptors are abundant in many areas of the brain including
the amygdala and hypothalamus.5 It has now been
hypothesised that progesterone is metabolised in the brain
to allopregnanolone and pregnanolone, which stimulates the
gamma-aminobutyric acid (GABA) inhibitory
neurotransmitter system. GABAA receptors are associated
with alterations in mood, cognition, and affect.9
In high concentrations pregnanolone and
allopregnanolone produce anxiolytic, sedative and
anaesthetic effects, however at lower levels allopregnanolone
can cause anxiety, negative mood and aggression. The GABA
receptors become less sensitive to allopregnanolone after
exposure to high concentrations, and hence the worsened
symptoms experienced during the luteal phase.9
Serotonergic activity in the brain is also affected by
estrogen and progesterone. Progesterone increases
monoaimine oxidase (MAO), which decreases the
availability of 5-hydroxytryptamine (5-HT), resulting in a
depressed mood. Whereas estrogen increases the degradation
of MAO, thus increasing the availability of free tryptophan in
the brain, which enhances serotonin transport, and therefore
stimulates 5-HT binding sites in the brain, resulting in an
antidepressant effect.10
100
Diagnosis
For an accurate diagnosis of PMS, prospective charting of
symptoms over two menstrual cycles is required. The Daily
Record of Severity of Problems (DRSP) is a well-validated
scale used in the diagnosis of PMS (Box 2).11,12 Prospective
documentation should demonstrate a presence of
symptoms during the luteal phase and resolution of
symptoms during menstruation. If there is a discrepancy
over the symptom pattern, then a third cycle of rating
should be carried out.13
The ISPMD first consensus reviewed the diagnostic criteria
for PMS.1 It highlighted the importance of an accurate
history of symptoms, which should be recorded for a
minimum of 2 months, as stated above. The symptoms
should be present during the premenstrual phase and absent
during the follicular phase, as well accurately recording
symptoms on a symptom chart.
Many patients find conscientious completion of charts
difficult. A new App, PreMentricS is now available (currently
iPhones only [Feb 2015]) which graphically documents
symptoms, provides a diagnosis, and monitors therapy
(Figure 1). It differs from previous charts but has yet to be
scientifically validated.
Patient perspective
One woman had been under the care of psychiatrists,
with regular psychiatric admissions premenstrually. Her
diagnoses included bipolar disorder and borderline
personality disorder but PMS was diagnosed through
prospective charting. The woman’s symptoms were so
persistent (including progestogen-induced PMS when on
estrogen treatment) that she requested a hysterectomy
with bilateral salpingoophorectomy (BSO) at the age of 28
despite not having children. After much debate she
underwent surgery. Post-surgery and estrogen replacement,
the woman commenced a university degree and remained
symptom-free.
A quotation from another woman highlighted how
debilitating PMS can be to social and family life: “GnRH
followed by estrogen and Mirena saved my marriage”.
Treatment
Management of PMS is usually performed in a step-wise
manner from non-pharmacological strategies, antidepressant
medications, hormonal strategies, with surgical options being
a last resort.
Women should have their symptoms confirmed by
prospective charting, and only when other underlying
medical and psychiatric conditions have been addressed
should treatment be commenced.
ª 2015 Royal College of Obstetricians and Gynaecologists

Box 2. Item content of the Daily Record of Severity of
Problems (DRSP)11
1a. Felt depressed, sad, ‘down,’ or ‘blue’
1b. Felt hopeless
1c. Felt worthless, or guilty
2. Felt anxious, tense, ‘keyed up’ or ‘on edge’
3a. Had mood swings (e.g., suddenly felt sad or tearful)
3b. Was more sensitive to rejection or my feelings were easily hurt
4a. Felt angry, irritable
4b. Had conflicts or problems with people
5. Had less interest in usual activities (e.g., work, school, friends,
hobbies)
6. Had difficulty concentrating
7. Felt lethargic, tired, fatigued, or had a lack of energy
8a. Had increased appetite or over-ate
8b. Had cravings for specific foods
9a. Slept more, took naps, found it hard to get up when intended
9b. Had trouble getting to sleep or staying asleep
10a. Felt overwhelmed or that I could not cope
10b. Felt out of control
11a. Had breast tenderness
11b. Had breast swelling, felt ‘bloated’, or had weight gain
11c. Had headache
11d. Had joint or muscle pain
• At work, at school, at home, or in daily routine, at least one of
the problems noted above caused reduction of productivity
or inefficiency.
• At least one of the problems noted above interfered with
hobbies or social activities (e.g., avoid or do less).
• At least one of the problems noted above interfered with
relationships with others.
Women with presumed PMS should initially be
investigated for other conditions such as depression,
anxiety disorders, and hypothyroidism, with referral to the
appropriate medical specialty, and adequate communication
Figure 1. Symptom view and diagnosis of woman with typical (core) premenstrual disorder generated by the PreMentricS App (Permission
Granted by PMS O’Brien).
ª 2015 Royal College of Obstetricians and Gynaecologists
Walsh et al.
with their general practitioner. There are links between PMS
and sexual abuse, as well as with post-traumatic stress
disorder, and therefore a full history to assess these aspects
should be obtained.14
Non-pharmacological treatment
A course of cognitive behavioural therapy (CBT) to address
relaxation, stress management, and assertiveness training,
has been reported to be effective in mild PMS, with success
being comparable to treatment with fluoxetine.10 Successful
CBT could avoid the need for pharmacotherapy; studies
have shown a more sustained but less rapid improvement
with the use of selective serotonin reuptake
inhibitors (SSRIs).
Complementary therapies
Rigorous research on complementary therapies for the
treatment of PMS is limited, with few well designed
randomised controlled trials. One study on the extract of
the Agnus cactus fruit (Vitex agnus castus) showed
improvement in PMS symptoms in up to 52% of
patients,14 however the trial numbers were small.
Alternative therapies such as exercise, dietary changes and
relaxation may help reduce PMS symptoms, and can improve
general health, but have not been scientifically proven.15,16
Antidepressants
The use of selective SSRIs, particularly fluoxetine 20–60 mg,
paroxetine 20–30 mg, citalopram 20–40 mg and sertraline
50–150 mg, has shown a substantial reduction in the
emotional, behavioural and physical symptoms in the
treatment of core PMD. The short onset of action of SSRIs
in women with PMS, means that SSRIs can be taken 14 days
101
 An overview of the current management of PMS
before menses, as well as continuously.12,14 A meta-analysis
on randomised control trials which involved SSRIs in the
management of PMS, showed the efficacy of SSRIs compared
to placebo.18–23Many studies suggest that intermittent SSRI
use is as effective as continuous use in reducing irritability
and other mood symptoms, but less effective in reducing
somatic symptoms. It is important to note that the European
Medicines Agency agrees that SSRIs seem to work in PMS,
and certain SSRIs are approved in parts of the world (for
example USA for PMDD). However neither the use of
intermittent nor continuous SSRI treatments are licensed in
the UK and when they are used they are off-licence.12,24–27
Patients should be informed of side effects including
nausea, fatigue, insomnia and sexual dysfunction, and that
side effects are less with intermittent use.6 Unfortunately
PMS symptoms recur following discontinuation of SSRIs.38
There can be significant effects if used during the course of
pregnancy even if this is only the initial stages. Women who
have failed two or more SSRI trials should probably try
hormonal treatment.19
The ISPMD second consensus further supports the use of
SSRIs,10 and within the second consensus it was found that
SSRI use as a first-line treatment was the most important
recommendation in the management of PMS, as well as
highlighting the importance of explaining the side effects
associated with the use of SSRIs. In practice this means that a
diagnosis should be accurately ascertained and a systematic
approach to the management of starting with SSRIs should
be utilised.
Estrogen
Estrogen therapy which inhibits ovulation has been proposed
as a method for management in PMS.28,29 Estrogen is usually
administered as a transdermal patch, or subcutaneous
implant,29 and is an effective agent in the treatment of
PMS. Transdermal patches are more readily available within
the UK, and hence are a frequent choice compared to the
implant. Receiving unopposed estrogen will require
progestogen cover to prevent endometrial hyperplasia,
unless the woman has had a hysterectomy. Progesterone
itself can cause PMS like symptoms, and therefore the lowest
dose possible, for the shortest time is recommended. The side
effects from synthetic progestins can be minimised through
the use of micronised progesterone, which is identical to that
produced by the corpus luteum.30 Alternatively
administration of progesterone directly to the endometrium
using the levonorgestrel-containing intrauterine system may
reduce recurrence of progesterone-induced PMS symptoms
in the long term. A few months after insertion there are
minimal systemic levels of progesterone. Although
excellent endometrial protection is provided, patients
should be advised that initially PMS like symptoms
may occur.12,29
102
Oral contraceptives
Newer oral contraceptives containing drospirenone 3 mg and
ethinyl estradiol 20 micrograms have shown a positive
improvement in PMS symptoms, when hormones were
administered for 24 days, followed by 4 days of inactive pills,
compared to placebo.32–34 However, due to the increased risk
of venous thromboembolism, this group of medication is not
suitable for all women. Unfortunately although this
treatment is licensed in the USA for PMS it is not
in the UK.34
No benefit has been found through the use of progesterone
alone – additionally the older combined oral contraceptive
pills appear to have no benefit in the treatment of PMS.35,36
Gonadotropin-releasing hormone (GnRH) analogues
Long-acting GnRH analogues suppress ovarian functioning,
reducing the levels of estradiol and progesterone, and
subsequently inhibit the menstrual cycle. Several
randomised controlled trials have demonstrated
improvement of premenstrual symptoms, with a response
rate to GnRH analogue treatment between 60% and 75%. A
meta-analysis concluded that, compared to placebo,
treatment with GnRH analogues resulted in significant
symptom relief in behavioural and physical
PMS symptoms.12,37
Although GnRH analogues seem like a good long-term
option for patients with severe PMS, they induce a hypo-
estrogenic state and eliminate ovulation.6 In the short term
this results in hot flushes, night sweats, low mood and
insomnia. More importantly, in the long term, risks of this
estrogen deficiency include vaginal atrophy, increased
cardiovascular risk and osteoporosis.6,12 Because of these
long-term risks, treatment without add–back therapy should
only be continued for 6 months. If women are receiving
add–back therapy on a long-term basis, they should have
assessment of bone mineral density. Although hormone
replacement therapy can be administered to reduce the effects
of estrogen deficiency, this in itself can re-stimulate PMS
like symptoms.
Due to the long-term risks of GnRH analogue use, they
should be reserved for women with the most severe
symptoms, or where other treatments have failed. In those
who fail to respond to GnRH analogues then the diagnosis of
PMS should be questioned.
Hysterectomy and bilateral salpingo-oophorectomy
(BSO)
Surgical options should be considered only as a last resort,
and a trial of GnRH with positive effect is advisable before
deciding to perform BSO and hysterectomy.
Hysterectomy with BSO has a beneficial effect on both
mood and physical symptoms. Oophorectomy alone would
stop PMS symptoms, but hysterectomy is required to ensure
ª 2015 Royal College of Obstetricians and Gynaecologists

estrogen replacement post-surgery can be unopposed
without the risk of endometrial hyperplasia, and thus
prevent the PMS side effects associated with progestogens.
Success rates of hysterectomy with BSO are high and long-
lasting, and now surgical intervention can usually be
performed laparoscopically, it is less invasive than
previously.38,39 It is important to remember that all surgical
procedures carry an anaesthetic risk, as well as the risk of
surgical complications. Surgery undertaken for a mood
disorder is unique to PMS management.
Surgery will render the woman infertile and induces the
menopause. Estrogen replacement therapy should be
commenced post-surgery to prevent the effects of
long-term estrogen deficiency, and should be continued
until the age when menopause naturally occurs.12
Importantly of course is the absence of endometrium, the
estrogen can be administered without the requirement for
protective progestogen
Ongoing assessment
It is important to remember that if a woman has not
responded to more than one pharmacological treatment, they
should be reassessed for potential underlying psychiatric or
medical disorders, therefore highlighting the importance of
regular patient review following initiation of treatment.
Contribution of authorship
SW: extensive literature search around the topic, and
significant contribution to the writing of the main article,
as well as referencing, and creation of several of the CPD
questions. EI: creation of several of the CPD questions,
appraisal of the article content and construction of the
abstract. BN: contribution into the design of the article, with
contribution in to the content and critical appraisal of the
overall article, as well as creation of several CPD questions.
SO: clinical supervisor who came up with the proposed idea
for the paper, with significant input in to the formatting
and content.
Disclosure of interests
None
References
1 O’Brien PMS, B€ackstr€om T, Brown C, Dennerstein L, Endicott J, Epperson
CN, et al. Towards a consensus on diagnostic criteria, measurement and
trial design of the premenstrual disorders: the ISPMD Montreal consensus.
Arch Womens Ment Health 2011;14:13–21.
2 Yonkers KA, O’Brien PM, Eriksson E. Premenstrual syndrome. Lancet
2008;371:1200–10.
3 Dhingra V, O’Brien SPM. Quantification of premenstrual syndrome and
premenstrual dysphoric disorder. In: O’Brien PMS, Rapkin A, Schmidt P,
editors. The Premenstrual Syndromes: PMS and PMDD. London: Informa
Healthcare; 2007. p. 27–36.
ª 2015 Royal College of Obstetricians and Gynaecologists
Walsh et al.
4 Pearlstein T, Yonkers KA, Fayyad R, Gillespie JA. Pretreatment pattern of
symptom expression in premenstrual dysphoric disorder. J Affect Disord
2005;85:275–82.
5 O’Brien S, Rapkin A, Dennerstein L, Nevatte T. Diagnosis and management
of premenstrual disorders. BMJ 2011;342:d2994.
6 Kadian S, O’Brien S. Classification of premenstrual disorders as proposed by
the International Society for Premenstrual Disorders. Menopause Int
2012;18:43–7.
7 Rapkin AJ, Kuo J. Neurotransmitter physiology: the basics for understanding
premenstrual syndrome. In: O’Brien PMS, Rapkin A, Schmidt P, editors. The
Premenstrual Syndromes: PMS and PMDD. London: Informa Healthcare;
2007. p. 69–71.
8 Pearlstein T, Yonkers KA, Fayyad R, Gillespie JA. Pretreatment pattern of
symptom expression in premenstrual dsyphoric disorder. J Affect Disord
2005;85:275–82.
9 Spinelli MG. Depression and hormone therapy. Clin Obstet Gynecol
2004;47:428–36.
10 Hunter MS, Ussher JM, Cariss M, Browne S, Jelley R, Katz M. Medical
(fluoxetine) and psychological (cognitive-behavioural therapy) treatment for
premenstrual dysphoric disorder. a study of treatment processes. J
Psychosom Res 2002;53:811–7.
11 Endicott J, Nee J, Harrison W. Daily Record of Severity of Problems (DRSP):
reliability and validity. Arch Womens Ment Health. 2006;9:41–9.
12 Borenstein JE, Dean BB, Yonkers KA. Endicott. Using the daily record of
severity of problems as a screening instrument for premenstrual syndrome.
Obstet Gynecol 2007;109:1068–75.
13 Nevatte T, O’Brien PMS, B€ackstr€ om T, Brown C, Dennerstein L, Endicott J,
et al. ISPMD consensus on the management of premenstrual disorders.
Arch Womens Ment Health 2013;16:279–91.
14 Perkonigg A, Yonkers KA, Pfister H, Lieb R, Wittchen HU. Risk factors for
premenstrual dysphoric disorder in a community sample of young women:
the role of traumatic events and posttraumatic stress disorder. J Clin
Psychiatry 2004;65:1314–22.
15 Stevinson C, Ernst E. Complementary/alternative therapies for premenstrual
syndrome: a systematic review of randomized controlled trials. Am J Obstet
Gynecol 2001;185:227–34.
16 Schellenberg R. Treatment for the premenstrual syndrome with agnus
castus fruit extract: prospective, randomised, placebo controlled study. BMJ
2001;322:134–7.
17 Royal College of Obstetricians and Gynaecologists. Premenstrual syndrome,
Management (Green-top Guideline No. 48). London:RCOG; 2007 [https://
www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg48/].
18 Dimmock PW, Wyatt KM, Jones PW, O’Brien PM. Efficacy of selective
serotonin-reuptake inhibitors in premenstrual syndrome: a systematic
review. Lancet 2000;356:1131–6.
19 Wikander I, Sundblad C, Andersch B, Dagnell I, Zylberstein D, Bengtsson
F, et al. Citalopram in premenstrual dysphoria: is intermittent treatment
during luteal phases more effective than continuous medication
throughout the menstrual cycle? J Clin Psychopharmaocol 1998;
18:390–8.
20 Pearlstein TB, Stone AB, Lund SA, Scheft H, Zlotnick C, Brown WA.
Comparison of fluoxetine, buproprion, and placebo in the treatment of
premenstrual dysphoric disorder. J Clin Psychopharmacol 1997;17:261–5.
21 Cohen LS, Soares CN, Yonkers KA, Bellew KM, Bridges IM, Steiner M.
Paroxetine controlled release for premenstrual dysphoric disorder: a double-
blind, placebo-controlled trial. Psychosom Med 2004;66:707–13.
22 Jermain DM, Preece CK, Sykes RL, Kuehl TJ, Sulak PJ. Luteal phase
sertraline treatment for premenstrual dysphoric disorder. Results of a
double-blind, placebo-controlled, crossover study. Arch Fam Med
1999;8:328–32.
23 Marjoribanks J, Brown J, O’Brien PM, Wyatt K. Selective serotonin reuptake
inhibitors for premenstrual syndrome. Cochrane Database Syst Rev 2013;
(6):CD001396.
24 Cohen LS, Miner C, Brown EW, Freeman E, Halbreich U, Sundell K, et al.
Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a
placebo-controlled, clinical trial using computerized diaries. Obstet Gynecol
2002;100:435–44.
25 Halbreich U, Bergeron R, Yonkers KA, Freeman E, Stout AL, Cohen L.
Efficacy of intermittent, luteal phase sertraline treatment of premenstrual
dysphoric disorder. Obstet Gynecol 2002;100:1219–29.
103
 An overview of the current management of PMS
26 Miner C, Brown E, McCray S, Gonzales J, Wohlreich M. Weekly luteal-phase
dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric
disorder: a randomized, double-blind, placebo-controlled clinical trial. Clin
Ther 2002;24:417–33.
27 Landen M, Nissbrandt H, Allgulander C, So€rvik K, Ysander C, Eriksson E.
Placebo-controlled trial comparing intermittent and continuous paroxetine
in premenstrual dysphoric disorder. Neuropsychopharmacology
2007;32:153–61.
28 Watson NR, Studd JW, Savvas M, Garnett T, Baber RJ. Treatment of severe
premenstrual syndrome with oestradiol patches and cyclical oral
norethisterone. Lancet 1989;2:730–2.
29 Yonkers , O’Brien PM, Eriksson E. Premenstrual syndrome. Lancet
2008;371:1200–10.
30 De Lignieres B. Oral micronized progesterone. Clin Ther 1999;21:41–60;
discussion 1-2.
31 Magos AL, Brincat M, Studd JW. Treatment of the premenstrual syndrome
by subcutaneous estradiol implants and cyclical oral norethisterone:
placebo-controlled study. BMJ 1986;292:1629–33.
32 Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin
A. Efficacy of a new low-dose oral contraceptive with drospirenone in
premenstrual dysphoric disorder. Obstet Gynecol 2005;106:492–501.
33 Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing
drospirenone for premenstrual syndrome. Cochrane Database of Syst Rev
2012;(2):CD006586.
104
34 Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment
of premenstrual dysphoric disorder with a new drospirenone-
containing oral contraceptive formulation. Contraception 2005;
72:414–21.
35 Ford O, Lethaby A, Roberts H, Mol BWJ. Progesterone for
premenstrual syndrome. Cochrane Database Syst Rev 2012;(3):
CD003415.
36 Graham CA, Sherwin BB. A prospective treatment study of premenstrual
symptoms using a triphasic oral contraceptive. J Psychosom Res
1992;36:257–66.
37 Wyatt KM, Dimmock PW, Ismail KM, Jones PW, O’Brien PM. The
effectiveness of GnRHa with and without ‘add-back’ therapy in
treating premenstrual syndrome: a meta analysis. BJOG 2004;
111:585–93.
38 Cronje WH, Vashisht A, Studd JW. Hysterectomy and bilateral
oophorectomy for severe premenstrual syndrome. Hum Reprod
2004;19:2152–5.
39 Casper RF, Hearn MT. The effect of hysterectomy and bilateral
oophorectomy on women with severe premenstrual syndrome. Am J Obstet
Gynecol 1990;162:105–109.
40 Pearlstein T, Joliat MJ, Brown EB, Miner CM. Recurrence of symptoms of
premenstrual dysphoric disorder after the cessation of luteal-phase
fluoxetine treatment. Am J Obstet Gynecol. 2003 Apr;
188:887–95.
ª 2015 Royal College of Obstetricians and Gynaecologists